In contrast, a preprint paper has reported that SARS-CoV-2 preferably bind to ACE2-expressed cholangiocytes rather than hepatocytes indicating that the variable liver injury observed in COVID-19 is probably related to cholangiocyte dysfunction rather than hepatocellular (39). This evidence concerns the gene ACE2 and COVID-19.